Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the month of November 2021. The report, dated November 12, 2021, incorporates by reference a press release (Exhibit 99.1) and is signed by Mondher Mahjoubi, Chairman of the Executive Board and CEO.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a cover sheet incorporating a press release rather than a financial statement.
Material Changes
The filing text does not disclose material changes versus prior periods. Specific operational or financial updates are contained within the incorporated press release, which is not detailed in the provided text.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or unusual items. These details are expected to be found in the referenced Exhibit 99.1 press release.
Investor Verification Checklist
- Review the full text of the press release dated November 12, 2021 (Exhibit 99.1) for specific operational updates.
- Verify the incorporation of this report into the Form F-3 registration statement (File No. 333-252074).
- Confirm if the press release contains new clinical data, partnership announcements, or regulatory milestones.